



Indication	Target	Candidate	Research	Hit	Lead	Pre-clinic	FIH Phase 0	Phase I	Phase II	Sponsor / Licensee
FAP Expressing Tumors	Fibroblast Activation Protein (FAP)	FAP-2286	¹⁷⁷ Lu							NOVARTIS
			²²⁵ Ac							
			⁶⁸ Ga							
FAP Expressing Tumors	Fibroblast Activation Protein (FAP)	3BP-5201	⁶⁸ Ga ¹⁸ F							3B Pharmaceuticals
		3BP-4961	^{99m} Tc							
NTR Expressing Tumors	Neurotensin Receptor (NTR)	FPI-2059 (IPN-01087) (3BP-227)	²²⁵ Ac				¹⁷⁷ Lu			Fusion Pharmaceuticals Inc.
			¹¹¹ In							
Neuroendocrine Tumors	Gastric Inhibitory Polypeptide Receptor (GIP-R)	3BP-3775								3B Pharmaceuticals
			⁶⁸ Ga							
CAIX Expressing Tumors	Carbonic Anhydrase IX (CAIX)	DPI-4452	¹⁷⁷ Lu							Debiopharm
			⁶⁸ Ga							
Solid Tumors	Undisclosed	NTA								CLOVIS ONCOLOGY
Solid Tumors	Undisclosed	NTB								CLOVIS ONCOLOGY
Solid Tumors	Undisclosed	NTC								CLOVIS ONCOLOGY
Solid Tumors	P-Cadherin	3BP	¹⁷⁷ Lu							3B Pharmaceuticals
			⁶⁸ Ga							
Solid Tumors	Urokinase-Type Plasminogen Activator Receptor (uPAR)	3BP	¹⁷⁷ Lu							3B Pharmaceuticals
			⁶⁸ Ga							
Solid Tumors	Undisclosed	3BP								3B Pharmaceuticals
Solid Tumors	Undisclosed	3BP								3B Pharmaceuticals
Solid Tumors	Undisclosed	3BP								3B Pharmaceuticals

 THERAPEUTIC RADIOPHARMACEUTICAL
 SPECT OR PET IMAGING AGENT